PubMed 23612425

Referenced in Channelpedia wiki pages of: none

Automatically associated channels: Kir2.3

Title: Structure, function and clinical relevance of the cardiac conduction system, including the atrioventricular ring and outflow tract tissues.

Authors: Halina Dobrzynski, Robert H Anderson, Andrew Atkinson, Zoltan Borbas, Alicia D'Souza, John F Fraser, Shin Inada, Sunil J R J Logantha, Oliver Monfredi, Gwilym M Morris, Anton F M Moorman, Thodora Nikolaidou, Heiko Schneider, Viktoria Szuts, Ian P Temple, Joseph Yanni, Mark R Boyett

Journal, date & volume: Pharmacol. Ther., 2013 Aug , 139, 260-88

PubMed link:

It is now over 100years since the discovery of the cardiac conduction system, consisting of three main parts, the sinus node, the atrioventricular node and the His-Purkinje system. The system is vital for the initiation and coordination of the heartbeat. Over the last decade, immense strides have been made in our understanding of the cardiac conduction system and these recent developments are reviewed here. It has been shown that the system has a unique embryological origin, distinct from that of the working myocardium, and is more extensive than originally thought with additional structures: atrioventricular rings, a third node (so called retroaortic node) and pulmonary and aortic sleeves. It has been shown that the expression of ion channels, intracellular Ca(2+)-handling proteins and gap junction channels in the system is specialised (different from that in the ordinary working myocardium), but appropriate to explain the functioning of the system, although there is continued debate concerning the ionic basis of pacemaking. We are beginning to understand the mechanisms (fibrosis and remodelling of ion channels and related proteins) responsible for dysfunction of the system (bradycardia, heart block and bundle branch block) associated with atrial fibrillation and heart failure and even athletic training. Equally, we are beginning to appreciate how naturally occurring mutations in ion channels cause congenital cardiac conduction system dysfunction. Finally, current therapies, the status of a new therapeutic strategy (use of a specific heart rate lowering drug) and a potential new therapeutic strategy (biopacemaking) are reviewed.